Sol-Gel Technologies Ltd. Stock

Equities

SLGL

IL0011417206

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-04-24 pm EDT 5-day change 1st Jan Change
0.92 USD -0.56% Intraday chart for Sol-Gel Technologies Ltd. +7.36% -16.74%
Sales 2024 * 2.4M Sales 2025 * 6.1M Capitalization 25.63M
Net income 2024 * -19M Net income 2025 * -14M EV / Sales 2024 * 10.7 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 4.2 x
P/E ratio 2024 *
-1.31 x
P/E ratio 2025 *
-2.24 x
Employees 36
Yield 2024 *
-
Yield 2025 *
-
Free-Float 34.83%
More Fundamentals * Assessed data
Dynamic Chart
Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sol-Gel Technologies Ltd. Elects Yuval Yanai as External Director CI
Transcript : Sol-Gel Technologies Ltd. - Special Call
Sol-Gel Technologies Ltd. Screens First Patient for SGT-610 Phase 3 Study CI
Sol-Gel Technologies Ltd. Announces Resignation of Shmuel Ben Zvi from Board CI
HC Wainwright Cuts Sol-Gel Technologies' Price Target to $9 From $12, Keeps Buy Rating MT
Sol-Gel Technologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
HC Wainwright Adjusts Price Target on Sol-Gel Technologies to $12 From $19, Keeps Buy Rating MT
Raymond James Adjusts Price Target on Sol-Gel Technologies to $7 From $9, Maintains Strong Buy Rating MT
Sol-Gel Technologies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Sol-Gel Technologies Ltd. Appoints Sharon Kochan to the Board of Directors CI
Raymond James Adjusts Sol-Gel Technologies' Price Target to $9 From $10, Keeps Strong Buy Rating MT
Sol-Gel Technologies, Searchlight Pharma Sign Licensing Deals for 2 Dermatology Drugs MT
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO and EPSOLAY in Canada CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news

Latest transcript on Sol-Gel Technologies Ltd.

1 day-0.56%
1 week+7.36%
Current month-6.13%
1 month-6.12%
3 months-20.00%
6 months-38.67%
Current year-16.74%
More quotes
1 week
0.89
Extreme 0.8946
1.00
1 month
0.79
Extreme 0.79
1.07
Current year
0.79
Extreme 0.79
1.58
1 year
0.79
Extreme 0.79
4.05
3 years
0.79
Extreme 0.79
14.80
5 years
0.00
Extreme 0
21.00
10 years
0.00
Extreme 0
21.00
More quotes
Managers TitleAgeSince
Founder 62 97-10-27
Director of Finance/CFO 56 17-01-31
Chief Operating Officer 48 09-12-31
Members of the board TitleAgeSince
Director/Board Member 55 23-07-25
Director/Board Member 50 18-09-12
Chairman 69 13-12-31
More insiders
Date Price Change Volume
24-04-24 0.92 -0.56% 7,564
24-04-23 0.9252 -1.05% 8,832
24-04-22 0.935 -0.53% 15,611
24-04-19 0.94 +4.43% 11,957
24-04-18 0.9001 +5.04% 4,553

Delayed Quote Nasdaq, April 24, 2024 at 04:30 pm EDT

More quotes
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.92 USD
Average target price
8 USD
Spread / Average Target
+769.57%
Consensus